Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: Correlation with low molecular AGE adduct clearance
Authors:
- Alejandro GugliucciAGAlejandro Gugliucci
- Krista MehlhaffKMKrista Mehlhaff
- Eriko KinugasaEKEriko Kinugasa
- Hiroaki OgataHOHiroaki Ogata
- Ricardo HermoRHRicardo Hermo
- John SchulzeJSJohn Schulze
- Satoshi KimuraSKSatoshi Kimura
- 1 February 2007
- journal article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 377 (1-2) , 213-220
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Advanced Glycation End Products in Renal FailureJournal of Renal Nutrition, 2006
- Prevention and Repair of Protein Damage by the Maillard Reaction In VivoRejuvenation Research, 2006
- Influence of PON1 Polymorphisms on the Association between Serum Paraoxonase 1 and Homocysteinemia in a General PopulationClinical Chemistry, 2006
- Glycation free adduct accumulation in renal disease: the new AGEPediatric Nephrology, 2005
- Evaluation and treatment of coronary artery disease in patients with end-stage renal diseaseKidney International, 2005
- Hemodialysis – From Early Days to Tomorrow2005
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003
- Preservation of Paraoxonase Activity by Wine FlavonoidsAnnals of the New York Academy of Sciences, 2002
- Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failureThe Lancet, 1994
- Is paraoxonase related to atherosclerosisChemico-Biological Interactions, 1993